The hormone pills worked — until they didn't.
That is one of the most frustrating moments in breast cancer care. A woman with estrogen receptor-positive (ER-positive) metastatic breast cancer starts hormone therapy, often with a CDK4/6 inhibitor, and the cancer shrinks or holds steady for months or years. Then a scan shows growth again. The treatment did not fail because she did anything wrong. The cancer adapted. It found a way to keep its growth signal switched on even when the hormone it depends on is taken away.
On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved a new answer to that exact problem: giredestrant (brand name Wilserdly), taken by mouth once a day, combined with another oral drug, everolimus. It is approved for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors carry a specific change called an ESR1 mutation — the very change that lets many cancers outsmart standard hormone therapy.
In the phase 3 trial behind the approval, the combination kept cancer from growing for a median of 10.0 months, compared with 5.5 months on standard hormone therapy plus everolimus, in patients whose tumors had the ESR1 mutation. That is nearly double the time without progression, from a regimen made entirely of pills — no infusions, no injections.
This post explains what ESR1 mutations are, how giredestrant works differently from older hormone therapies, what the trial actually showed (including what it has not shown yet), who can get the drug, and the side effects — mouth sores chief among them — that are worth planning for from day one.
First, the Problem: When Hormone Therapy Stops Working
ER-positive breast cancers grow in response to estrogen. Hormone therapy (also called endocrine therapy) attacks that signal. Aromatase inhibitors lower the amount of estrogen in the body. Other drugs block the estrogen receptor itself. For many patients, these treatments work well for a long time.
But cancers evolve under pressure. One of the most common escape routes is a mutation in ESR1, the gene that builds the estrogen receptor. After months or years on an aromatase inhibitor, roughly 40% of patients whose cancer starts growing again have tumors with an acquired ESR1 mutation.
A lock that no longer needs a key
Think of the estrogen receptor as a lock, and estrogen as the key. Aromatase inhibitors work by taking the keys away — less estrogen, less growth signal. An ESR1 mutation changes the lock so it stays in the "on" position all by itself, no key required. It does not matter how little estrogen is left in the body. The signal keeps firing, and the cancer keeps growing.
That is why simply switching to another estrogen-lowering drug often disappoints after an ESR1 mutation appears. The problem is no longer the key. The problem is the lock.
The logical fix is a drug that does not just block the lock, but removes it. That is what giredestrant was built to do.
What Giredestrant Is — and Why It Is Different
Giredestrant belongs to a class of drugs called SERDs, short for selective estrogen receptor degraders. The name describes the job: the drug binds to the estrogen receptor and marks it for destruction, so the cancer cell has fewer receptors to signal with. Giredestrant is also a full antagonist, meaning it shuts the receptor's activity down completely rather than partially.
The older SERD, fulvestrant, has been used for years — but it is given as two large injections in the buttock each month, and it only partially degrades the receptor. A newer generation of oral SERDs aims to do the job better, with a daily pill. Giredestrant was designed to suppress estrogen receptor activity whether or not estrogen is present, and whether or not the receptor is mutated — exactly the situation an ESR1 mutation creates.
Why pair it with everolimus?
ESR1 mutations are not the only escape route. Many cancers also lean harder on a growth pathway called PI3K/AKT/mTOR. Everolimus is an oral drug that blocks the mTOR part of that pathway, and it has been a standard partner to hormone therapy in this setting for years.
The combination logic is straightforward: giredestrant removes the hormone signal, and everolimus blocks a backup growth pathway at the same time. Two escape routes, closed at once.
"The problem is no longer the key. The problem is the lock — so the new drug does not just block the lock, it removes it."
The Trial Behind the Approval: evERA
The approval rests on evERA, a phase 3 trial published in The New England Journal of Medicine in October 2026 and led by Dr. Erica Mayer of Dana-Farber Cancer Institute. The trial enrolled 373 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease had progressed or recurred after treatment with a CDK4/6 inhibitor plus hormone therapy — the standard first-line combination, and the point where options often narrow.
Patients were randomly assigned, 1 to 1, to one of two all-oral regimens:
- Giredestrant plus everolimus (183 patients): giredestrant 30 mg once daily, everolimus 10 mg once daily.
- Standard hormone therapy plus everolimus (190 patients): the doctor's choice of exemestane, fulvestrant, or tamoxifen, plus the same everolimus.
Everyone's tumor was tested for ESR1 mutations using a blood test (more on that below). Of the 373 patients, 207 — about 55% — had ESR1-mutated tumors. That share was deliberately higher than the roughly 40% seen in everyday practice, because the trial was designed to answer the ESR1 question first.
The main measure was progression-free survival: the time from starting treatment until the cancer grew or the patient died, whichever came first.
What the Trial Found
Finding #1: In ESR1-mutated cancer, the combo nearly doubled the time without progression
Among patients with ESR1-mutated tumors, the typical (median) time without progression was 10.0 months on giredestrant plus everolimus, versus 5.5 months on standard hormone therapy plus everolimus. In statistical terms, that is a 62% lower risk of the cancer progressing or the patient dying at any given moment (hazard ratio 0.38). This was the trial's headline result, and it is the population the FDA approved the drug for.
Finding #2: The benefit held across the whole trial population — but was driven by the ESR1 group
Looking at all 373 patients together, median time without progression was 8.8 months on the giredestrant combination versus 5.5 months on standard therapy — a 44% lower risk of progression or death (hazard ratio 0.56). That is a real result, but read Finding #4 before drawing conclusions from it.
Finding #3: More tumors shrank, and responses lasted about twice as long
Among patients with ESR1-mutated tumors and measurable disease, about 27% saw their tumors shrink significantly on the giredestrant combination, versus about 14% on standard therapy. When tumors did respond, the response lasted a median of 14.9 months versus 7.3 months. For someone weighing a next treatment, a response that lasts twice as long matters as much as the response itself.
Finding #4: Without an ESR1 mutation, there was no clear benefit
This is the finding that shapes the approval. In patients whose tumors had no detectable ESR1 mutation, time without progression was nearly identical between the two groups: 5.7 versus 5.5 months (hazard ratio 0.84, with a confidence range that includes no difference at all). The giredestrant advantage appears to live in the mutated group.
That is why the FDA approved the drug specifically for ESR1-mutated cancer, and why testing comes first. This is not a drug for every ER-positive patient — it is a drug matched to a specific tumor change.
Finding #5: Survival results are promising but not proven yet
The trial has not yet shown that the combination helps patients live longer. Survival data were described as "immature" — not enough time has passed. There is an encouraging trend: at 18 months, an estimated 71.5% of patients with ESR1-mutated tumors on the giredestrant combination were alive, versus 50.9% on standard therapy (hazard ratio 0.62). But the statistical range around that estimate still includes the possibility of no benefit, so the honest statement is: survival benefit is possible, not proven. Longer follow-up will tell.
Finding #6: Side effects were similar to the standard combination
Nearly everyone in both groups had some side effects (98.9% versus 96.8%), which is expected with everolimus-based therapy. The rates of most side effects were close between the two arms — the giredestrant combination did not appear to add a major new burden on top of what everolimus already causes. Serious side effects occurred in 29.1% versus 23.1%. The details matter, and they get their own section below.
A Blood Test Decides: The Companion Diagnostic
You cannot see an ESR1 mutation on a scan. Finding one used to mean a new tissue biopsy — another procedure, another wait. For this approval, the FDA also authorized the FoundationOne Liquid CDx assay, a blood test that looks for tumor DNA circulating in the bloodstream (often called a liquid biopsy). The ESR1 status of every patient in evERA was determined this way, from blood.
That matters practically. When ER-positive metastatic breast cancer starts growing on hormone therapy, a blood draw can now help answer "what changed?" — and if the answer is an ESR1 mutation, this approval is one of the options it points to. If you had a liquid biopsy earlier in your care, ask whether ESR1 was included and whether retesting at progression makes sense; mutations are acquired over time, so an old negative result does not rule out a mutation today.
The Side Effects Worth Planning For
Because both drugs in this combination are pills taken at home, much of the day-to-day management lands on the patient. Here is what the trial showed, and what helps.
Mouth sores (stomatitis) were the most common side effect — 47.3% of patients on the giredestrant combination (and 48.9% on the standard combination, because everolimus is the main driver). The good news: the vast majority were mild or moderate. Severe (grade 3) sores occurred in just 2.7%, and there were no grade 4 cases. The trial strongly recommended a preventive dexamethasone mouthwash, based on an earlier study called SWISH, and additional trial data suggest it works: patients using the mouthwash had fewer moderate sores (14.4% versus 21.1%), fewer severe sores (1.8% versus 4.2%), and a later onset (a median of 20 days versus 13). If you start this regimen, ask about the mouthwash before the first dose, not after the first sore. Mouth pain is also where nutrition quietly falls apart — our post on starting nutrition supplements early during chemoradiation covers how quickly mouth sores can turn into major weight loss, and why getting ahead of them matters.
Diarrhea affected 26.9% of patients on the combination — and notably, none of those cases were grade 3 or 4. Nausea (22.0%) and vomiting (11.5%) were also mostly mild. Even mild diarrhea and nausea, day after day, can drain fluids and electrolytes; keeping up with hydration is not a small thing on this regimen, and it is exactly the kind of everyday supportive care HuMOLYTE was designed around.
Fatigue (20.9%) and decreased appetite (18.7%) were common and similar to the control arm. Weight loss occurred in 10.4%. Tell your team early if eating is slipping — appetite loss plus mouth sores plus diarrhea is a combination that can snowball.
Pneumonitis — inflammation of the lungs — occurred in 17.0%, with 2.7% grade 3 or 4. This is a known everolimus effect and the one to respect most: a new cough, new shortness of breath, or fever should be reported the same day, not watched for a week.
Lab changes included anemia (23.6%), high blood sugar (12.6% — everolimus can raise glucose, so patients with diabetes should expect closer monitoring), and low potassium (12.1%). These are found on routine blood work, which is one reason the follow-up labs on this regimen are not optional.
Slow heart rate (bradycardia) is a labeled warning for giredestrant. In the trial it occurred in 3.8% of patients on the combination versus 0.5% on standard therapy — but every case was mild (grade 1), none required pausing treatment, and all resolved. Unlike some other oral SERDs, giredestrant showed no cases of photopsia (visual light disturbances). If you take heart-rate-lowering medicines, make sure your oncology team has the full list.
Quality of life held up. In patient-reported outcome data from the trial, quality of life was maintained on the combination, and at the start of the second cycle, 45% of patients on giredestrant plus everolimus said side effects bothered them "not at all," compared with 32% on the standard combination. Longer time without progression did not appear to come at the cost of feeling worse day to day.
"Ask about the preventive mouthwash before the first dose, not after the first sore."
Three Myths to Leave Behind
Myth 1: "It's a new kind of chemotherapy." No. Neither drug is chemotherapy. Giredestrant is hormone therapy — a more complete way of shutting down the estrogen receptor — and everolimus is a targeted therapy that blocks a growth pathway. There is no infusion, and the side-effect pattern is different from chemo: mouth sores, diarrhea, and lab changes rather than hair loss and low blood counts (though blood counts are still monitored).
Myth 2: "It works for all hormone receptor-positive breast cancer." The approval is narrower than that, on purpose. The clear benefit was in ESR1-mutated tumors. Without the mutation, the trial found no clear advantage over standard therapy. The blood test is not a formality — it is the point.
Myth 3: "It has been shown to help women live longer." Not yet. The survival trend favors the combination, but the data are immature and the result is not statistically proven. What is proven is longer time before the cancer grows, more tumor shrinkage, and longer-lasting responses. Anyone who promises more than that is ahead of the evidence.
What This Approval Does Not Do
A few honest limits. The evERA trial was open-label, meaning patients and doctors knew which treatment was given. The study population was enriched for ESR1 mutations, so the overall-population result should not be read as applying equally to everyone. Patients who had already received an oral SERD, or chemotherapy for metastatic disease, were not included. And the approval covers advanced disease — giredestrant for early-stage breast cancer is a separate question, with an FDA decision expected on November 30, 2026. If that application succeeds, it would be the first new hormone therapy approved for early-stage disease in more than two decades — but it has not happened yet, and it is a different decision from this one.
It is also worth saying what this means alongside the bigger survivorship picture. Every added month of disease control in metastatic cancer is a month of living with treatment — its labs, its side effects, its daily management. Our recent post on how chemotherapy may speed up biological aging in survivors is a reminder that long-term care planning matters alongside each new approval.
Signs Worth Reporting Promptly on This Regimen
- Mouth sores that make eating or drinking painful, or that do not improve within a few days
- A new cough, new shortness of breath, or fever (possible lung inflammation)
- Diarrhea that lasts more than a day or two, or any dizziness or lightheadedness with it
- Unusual bruising, bleeding, or exhaustion that could signal low blood counts
- Feeling faint, or a noticeably slow pulse
- Rash that spreads, blisters, or involves the mouth or eyes
- Appetite loss or weight loss that continues week over week
- Increased thirst or urination, which can signal rising blood sugar
Questions to Ask Your Oncology Team
- Has my tumor been tested for an ESR1 mutation — and if the test was done a while ago, should it be repeated now that my cancer is growing?
- Was the test a blood-based liquid biopsy, and which mutations did it cover?
- Given my treatment history, does this approval apply to me — including my prior CDK4/6 inhibitor and hormone therapy?
- How does giredestrant plus everolimus compare with my other options at this point, including clinical trials?
- Should I start the dexamethasone mouthwash to prevent mouth sores, and when exactly do I begin it?
- What is the plan for monitoring my blood counts, potassium, blood sugar, and liver tests?
- I take medicines that can slow the heart rate. Do any of them interact with giredestrant's bradycardia warning?
- What symptoms should make me call the same day rather than wait for my next visit?
- If diarrhea, nausea, or mouth pain make it hard to eat and drink, what is our plan for hydration and nutrition support?
- If this combination stops working, what would come next?
The Bottom Line
- On November 16, 2026, the FDA approved giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation, identified by an FDA-authorized test.
- In the evERA phase 3 trial (373 patients), the all-oral combination kept cancer from progressing for a median of 10.0 months versus 5.5 months in ESR1-mutated disease — a 62% lower risk of progression or death.
- Tumors shrank in about 27% versus 14%, and responses lasted about twice as long (14.9 versus 7.3 months).
- In tumors without an ESR1 mutation, there was no clear benefit — which is why the approval, and the blood test, are mutation-specific.
- A survival benefit is not yet proven; the trend is favorable and follow-up continues.
- The most common side effect is mouth sores (about 47%, almost all mild or moderate), and a preventive steroid mouthwash appears to reduce them. Diarrhea, fatigue, nausea, and lung inflammation are the other effects to know.
- The practical takeaway: when hormone therapy stops working in ER-positive metastatic breast cancer, ask about ESR1 testing. The answer now opens a specific, all-oral door that did not exist before this week.
Frequently Asked Questions
Is giredestrant chemotherapy?
No. Giredestrant is a hormone therapy drug — an oral SERD that blocks and degrades the estrogen receptor. Its partner, everolimus, is a targeted therapy. The combination is taken entirely as pills at home.
Who is eligible for Wilserdly (giredestrant)?
Adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have an ESR1 mutation found by an FDA-authorized test, and whose disease recurred during or after adjuvant hormone therapy or progressed on at least one hormone-based regimen in the metastatic setting. In the trial, all patients had previously received a CDK4/6 inhibitor plus hormone therapy.
How is the ESR1 test done?
With a blood test — the FoundationOne Liquid CDx assay, authorized by the FDA alongside the drug. It detects tumor DNA circulating in the blood, so a new tissue biopsy is usually not needed to check ESR1 status.
What if my tumor does not have an ESR1 mutation?
In evERA, patients without a detectable ESR1 mutation did not progress more slowly on the giredestrant combination than on standard therapy (5.7 versus 5.5 months). The drug is not approved for that group, and other options — including other targeted combinations and clinical trials — would usually be discussed instead.
Does giredestrant help patients live longer?
That has not been proven yet. Survival data from evERA were immature at the time of the analysis. The early trend favors the combination (an estimated 71.5% versus 50.9% alive at 18 months in the ESR1-mutated group), but the statistical range includes the possibility of no benefit. More follow-up is coming.
What are the most important side effects to watch?
Mouth sores are the most common (about 47%, mostly mild or moderate, and partly preventable with a dexamethasone mouthwash). Diarrhea, nausea, fatigue, and appetite loss are also common. The most serious to report immediately is lung inflammation (pneumonitis) — a new cough, breathlessness, or fever. The drug label also warns about slow heart rate.
How is giredestrant different from fulvestrant or elacestrant?
Fulvestrant is an older SERD given by monthly injections, and it degrades the receptor less completely. Elacestrant is an oral SERD approved as a single drug for ESR1-mutated disease; in trials, single-drug oral SERDs have generally kept cancer from progressing for under 6 months on median. Giredestrant is a next-generation oral SERD approved in combination with everolimus, and evERA is the first phase 3 trial in which such an all-oral SERD combination beat a standard hormone-therapy combination head-to-head after CDK4/6 inhibitor therapy.
Sources
1 U.S. Food and Drug Administration. "FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer." FDA, November 16, 2026. 2 Mayer EL, Tolaney SM, Martín M, et al. "Giredestrant plus Everolimus in Advanced Breast Cancer." The New England Journal of Medicine, October 1, 2026. 3 Genentech. "FDA Approves Roche's Wilserdly (giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer." GlobeNewswire, November 16, 2026. 4 Medscape. "QOL Maintained With Giredestrant Combo in Advanced BC." Medscape, 2026.
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.